Testing and validation of agents and mechanisms targeting mutant and wild-type variants of p53 open new perspectives for improving the therapeutic ratio of oncological therapies by enhancing tumor destruction and simultaneously protecting healthy tissues. This evidence concerns the gene TP53 and neoplasm.